This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.
18 Years and older.
- Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that
require IOP lowering treatment.
- Eye surgery (including cataract surgery) and or eye laser surgery within the past 6
- Previous use of commercially available Bimatoprost SR; c oncurrent enrollment in
another Allergan Bimatoprost SR study; or previous enrollment in which an implant was